Hanall Biopharma Co., Ltd. (KRX:009420)
42,650
+700 (1.67%)
At close: Dec 19, 2025
Hanall Biopharma Revenue
Hanall Biopharma had revenue of 40.80B KRW in the quarter ending September 30, 2025, with 10.76% growth. This brings the company's revenue in the last twelve months to 154.05B, up 14.76% year-over-year. In the year 2024, Hanall Biopharma had annual revenue of 138.94B with 2.99% growth.
Revenue (ttm)
154.05B
Revenue Growth
+14.76%
P/S Ratio
14.06
Revenue / Employee
506.75M
Employees
304
Market Cap
2.17T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138.94B | 4.03B | 2.99% |
| Dec 31, 2023 | 134.91B | 24.91B | 22.65% |
| Dec 31, 2022 | 110.00B | 8.40B | 8.27% |
| Dec 31, 2021 | 101.59B | 12.99B | 14.66% |
| Dec 31, 2020 | 88.60B | -19.85B | -18.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |